Related Experiment Videos
Structure-based virtual screening protocols.
1Bristol-Myers Squibb, 5 Research Parkway, Wallingford, CT 06492, USA. Andrew.Good@bms.com
Current Opinion in Drug Discovery & Development
|September 19, 2001
Summary
Structure-based virtual screening (SVS) is crucial for drug discovery. This review covers new SVS technologies, validation studies, and scoring methods, highlighting successes and limitations in identifying potential drug leads.
Area of Science:
- Computational chemistry
- Drug discovery
- Pharmacology
Background:
- Virtual screening is vital in pharmaceutical lead discovery.
- Structure-based virtual screening (SVS) utilizes 3-D target active sites.
- SVS is a key technology for identifying novel drug candidates.
Purpose of the Study:
- To review recent advancements in SVS technology.
- To highlight new methods for scoring ligand-protein interactions.
- To discuss validation experiments and limitations of current SVS approaches.
Main Methods:
- Review of recent literature on SVS.
- Analysis of new technologies in ligand interaction sampling.
- Examination of scoring functions for binding affinity prediction.
Main Results:
- Successful applications of SVS in lead discovery were identified.
- Current technological limitations in SVS were illustrated.
- Novel scoring and ligand sampling methods show promise.
Conclusions:
- SVS technology continues to evolve, improving drug discovery efficiency.
- Further development in scoring and sampling is needed to overcome limitations.
- SVS remains a powerful tool for identifying pharmaceutical leads.